Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Losigamone. Dr Willmar Schwabe.

L J Willmore1

  • 1Department of Neurology, Saint Louis University School of Medicine, MO 63104, USA. willmore@slu.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hippocampal gene network analysis in an experimental model of posttraumatic epilepsy.

Neurochemical research·2010
Same author

Lamotrigine.

Expert review of neurotherapeutics·2009
Same author

Posttraumatic epilepsy: hemorrhage, free radicals and the molecular regulation of glutamate.

Neurochemical research·2008
Same author

Predictive value of hippocampal MR imaging-based high-dimensional mapping in mesial temporal epilepsy: preliminary findings.

AJNR. American journal of neuroradiology·2006
Same author

Treatment of benign epilepsy syndromes throughout life.

Epilepsia·2002
Same author

Idiopathic cardiac asystole presenting as an intractable adult onset partial seizure disorder.

Seizure·2001
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Losigamone is an antiepileptic drug in development. Its exact mechanism is unclear, but it may involve K+ channel activation rather than direct GABA receptor interaction.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Development

Background:

  • Losigamone is an investigational antiepileptic drug developed by Schwabe.
  • The drug was in phase III clinical trials as of August 2000.
  • Schwabe was seeking partners for further development and trial completion.

Purpose of the Study:

  • To investigate the pharmacological profile and mechanism of action of losigamone.
  • To clarify losigamone's interaction with GABAergic systems and ion channels.

Main Methods:

  • In vitro studies examining interactions with GABA, flunitrazepam, and TBPS receptors.
  • Electrophysiological recordings in hippocampal slices to assess effects on inhibitory postsynaptic potentials (IPSPs).
  • Assays measuring GABA-induced chloride influx in primary neuron cultures.

Related Experiment Videos

Main Results:

  • Losigamone does not appear to involve specific binding to GABA, flunitrazepam, or TBPS receptors.
  • Conflicting data exist regarding its interaction with GABA-A receptor channels.
  • It did not significantly alter GABAergic IPSPs in hippocampal slices.
  • However, it potentiated GABA-induced chloride influx in spinal cord neuron cultures.
  • K+ channel activation is a suggested alternative mechanism.

Conclusions:

  • The precise mechanism of action for losigamone remains undetermined.
  • Evidence suggests it may not act via direct binding to common GABA receptor sites.
  • Potential roles in modulating GABAergic transmission and K+ channel activity warrant further investigation.